Benuvia to Acquire DEA-Approved Cannabis and Psychedelics from Bright Green for Pharmaceutical APIs

Leading pharmaceutical cannabis business Benuvia Operations has signed a letter of intent to purchase Bright Green Corporation's DEA-approved marijuana extracts and plant-based psychedelics. Bright Green's dedication to supply US pharmaceutical clients with premium organic ingredients is evidenced by this arrangement. In order to produce domestically manufactured cGMP pharmaceutical-grade Active Pharmaceutical Ingredients (APIs) for US and international markets, Benuvia will take advantage of Bright Green's unique position to produce Schedule I & II raw materials in full compliance with Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and the DEA, all within the USA.

With this action, Bright Green takes a step closer to being the primary domestic provider of DEA-controlled, plant-based raw materials for the manufacture of hallucinogenic, opiate, and cannabinoid medications in the United States. Bright Green is well-positioned to achieve great results in 2025, as new supplier agreements and funding rounds are being worked on.